




RealRate

PHARMACEUTICAL 2019

Sonnet BioTherapeutics Holdings Inc.
Rank 130 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

**RealRate**

PHARMACEUTICAL 2019

Sonnet BioTherapeutics Holdings Inc. Rank 130 of 371



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 541% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 545% points.

The company's Economic Capital Ratio, given in the ranking table, is -70%, being 261% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	1,675
Cost of Goods Sold	0
Intangible Assets	16,404
Liabilities, Current	14,312
Liabilities, Non-Current	3,000
Other Assets	1,247
Other Compr. Net Income	1,078
Other Expenses	40,689
Other Liabilities	4,223
Other Net Income	-2,545
Property and Equipment	10,468
Research and Development	0
Revenues	40,614
Selling, General and Administrative Expense	4,579

Output Variable	Value in 1000 USD
Assets	29,793
Liabilities	21,536
Expenses	45,268
Stockholders Equity	8,258
Net Income	-7,199
Comprehensive Net Income	-6,660
Economic Capital Ratio	-70%

**RealRate**

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai